{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:15:19Z","timestamp":1790651719134,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.hoc.2023.07.003","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T16:42:06Z","timestamp":1691858526000},"page":"1189-1199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy"],"prefix":"10.1016","volume":"37","author":[{"given":"Grace A.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2023.07.003_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2023.07.003_bib2","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.07.003_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10297","key":"10.1016\/j.hoc.2023.07.003_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.hoc.2023.07.003_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2023.07.003_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa","year":"2017","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1016\/j.hoc.2023.07.003_bib7","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2023.07.003_bib8","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2023.07.003_bib9","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T\u00a0cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.hoc.2023.07.003_bib10","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1182\/bloodadvances.2022007006","article-title":"Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL","volume":"6","author":"Perez","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2023.07.003_bib11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.hoc.2023.07.003_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2023.07.003_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.07.003_bib14","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/s41598-017-01800-6","article-title":"Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression","volume":"7","author":"Kazantseva","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.hoc.2023.07.003_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-018-0119-y","article-title":"CAR T\u00a0cell therapy: inroads to response and resistance","volume":"19","author":"Brown","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"13","key":"10.1016\/j.hoc.2023.07.003_bib16","first-page":"1832","article-title":"Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy","volume":"137","author":"Spiegel","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2023.07.003_bib17","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T\u00a0cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.07.003_bib18","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2022.40.16_suppl.7565","article-title":"Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL)","volume":"40","author":"Locke","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2023.07.003_bib19","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.hoc.2023.07.003_bib20","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s41375-019-0580-z","article-title":"Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19","volume":"34","author":"Asnani","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2023.07.003_bib21","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.23266","article-title":"Lineage switch in childhood acute leukemia: an unusual event with poor outcome","volume":"87","author":"Rossi","year":"2012","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.hoc.2023.07.003_bib22","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.07.003_bib23","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.21037\/tcr.2016.06.35","article-title":"Chimeric antigen receptor T\u00a0cells get passed by leukemia","author":"Locke","year":"2016","journal-title":"Transl Cancer Res"},{"issue":"1947","key":"10.1016\/j.hoc.2023.07.003_bib24","first-page":"20210229","article-title":"The roles of T\u00a0cell competition and stochastic extinction events in chimeric antigen receptor T\u00a0cell therapy","volume":"288","author":"Kimmel","year":"2021","journal-title":"Proc Biol Sci"},{"issue":"19","key":"10.1016\/j.hoc.2023.07.003_bib25","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.hoc.2023.07.003_bib26","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.07.003_bib27","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T\u00a0cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.hoc.2023.07.003_bib28","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T\u00a0cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.hoc.2023.07.003_bib29","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T\u00a0cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.07.003_bib30","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1182\/blood-2018-99-111523","article-title":"End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.07.003_bib31","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","article-title":"Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas","volume":"132","author":"Chong","year":"2018","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.07.003_bib32","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1200\/JCO.2023.41.16_suppl.2517","article-title":"Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501\/501A in relapsed\/refractory large B-cell lymphoma (r\/r LBCL)","volume":"41","author":"Locke","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2023.07.003_bib33","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.hoc.2023.07.003_bib34","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.07.003_bib35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T\u00a0cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"issue":"28","key":"10.1016\/j.hoc.2023.07.003_bib36","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"10299","key":"10.1016\/j.hoc.2023.07.003_bib37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2023.07.003_bib38","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/JCO.2020.38.15_suppl.3022","article-title":"Tumor microenvironment associated with increased pretreatment density of activated PD-1+ LAG-3+\/\u2212 TIM-3\u2212 CD8+ T\u00a0cells facilitates clinical response to axicabtagene ciloleucel (axi-cel) in patients (pts) with large B-cell lymphoma","volume":"38","author":"Galon","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.hoc.2023.07.003_bib39","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.hoc.2023.07.003_bib40","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2023.07.003_bib41","doi-asserted-by":"crossref","first-page":"581 e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.hoc.2023.07.003_bib42","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2023.07.003_bib43","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"26","key":"10.1016\/j.hoc.2023.07.003_bib44","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2023.07.003_bib45","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.hoc.2023.07.003_bib46","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.7150\/thno.76854","article-title":"Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.hoc.2023.07.003_bib47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"17","key":"10.1016\/j.hoc.2023.07.003_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159402","article-title":"Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T\u00a0cell responses","volume":"132","author":"Romain","year":"2022","journal-title":"J\u00a0Clin Investig"},{"issue":"7","key":"10.1016\/j.hoc.2023.07.003_bib49","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/annonc\/mdf185","article-title":"p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas","volume":"13","author":"Leroy","year":"2002","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2023.07.003_bib50","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2023.07.003_bib51","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-21-1559","article-title":"Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing","volume":"27","author":"Lemoine","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2023.07.003_bib52","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:21:02Z","timestamp":1760185262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0889858823001053"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.07.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}